Papadavid E, et al. - This trial was conducted to gauge the effectiveness and safety of apremilast, a small-molecule PDE4 inhibitor, in the treatment of patients with psoriasis. Apremilast produced ΔPASI75 and ΔPASI50 responses along with DLQI≤5 in 16 weeks in 70.4% of the patients, hence proved to be a safe and effective treatment option for the psoriasis patients. The efficacy and safety of apremilast which was demonstrated in large phase III clinical trials were confirmed in these findings from a real-world setting.